4.5 Review

Trigger Factors and Premonitory Features of Migraine Attacks: Summary of Studies

期刊

HEADACHE
卷 54, 期 10, 页码 1670-1679

出版社

WILEY
DOI: 10.1111/head.12468

关键词

migraine trigger; trigger factor; premonitory feature

资金

  1. Allergan Pharmaceuticals
  2. Merck, Inc.
  3. MAP Pharmaceuticals
  4. NuPathe
  5. Novartis
  6. Zogenix
  7. Shor Foundation for Epilepsy Research
  8. NIH [PO1 AG03949, RO1AG025119, RO1AG022374-06A2, RO1AG034119, RO1AG12101]
  9. National Headache Foundation
  10. Migraine Research Fund

向作者/读者索取更多资源

Objective.-In this second of a 2-part series, we review the available literature on trigger factors and premonitory features in migraine. Background.-In the absence of biological markers of preceding attacks of migraine, trigger factors and premonitory symptoms are valuable though methodologically challenging phenomena to study. Design/Methods.-We focus on selected studies of retrospective surveys, diary studies, and clinical trials. We review the heterogeneity of selected studies and their conclusions performed to date and highlight that prospective electronic diary studies provide most reliable information that can be used for future development of preemptive therapy. Conclusion.-We conclude that trigger factors and premonitory symptoms are very common, but that the frequency estimates vary widely based on the study approach and population. We recommend that multimodal approaches are necessary for the comprehensive study of predictive biophenotypes as determined by triggers and premonitory symptoms, including retrospective and prospective cohort studies and case-crossover studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据